Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.38 |
| ▸ | MAP3K12 | Q12852 | 2/20 | 0.33 |
| ▸ | FPR1 | P21462 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 2/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | PDE1A | P54750 | 1/20 | 0.32 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.32 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.32 |
| ▸ | SPR | P35270 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24007242 | 1.00 | BRD4 (0.38) | BRD4CREBBPMAP3K12FPR1CNR2 | |
| SCHEMBL24007834 | 0.87 | CNR2 (0.35) | BRD4CREBBPMAP3K12FPR1CNR2 | |
| SCHEMBL24007027 | 0.87 | CNR2 (0.35) | BRD4CREBBPMAP3K12FPR1CNR2 | |
| SCHEMBL25746244 | 0.85 | FPR1 (0.34) | MAP3K12FPR1CNR2PDE1APDE1B | |
| SCHEMBL25746250 | 0.85 | FPR1 (0.34) | MAP3K12FPR1CNR2PDE1APDE1B | |
| SCHEMBL24816262 | 0.83 | BRD4 (0.39) | BRD4CREBBPMAP3K12FPR1CNR2 | |
| SCHEMBL24007684 | 0.81 | PDE1A (0.32) | MAP3K12FPR1CNR2PDE1APDE1B | |
| SCHEMBL24007359 | 0.81 | PDE1A (0.32) | MAP3K12FPR1CNR2PDE1APDE1B | |
| SCHEMBL26008990 | 0.80 | PDE1A (0.39) | BRD4CREBBPMAP3K12FPR1CNR2 | |
| SCHEMBL24007247 | 0.80 | BRD4 (0.39) | BRD4CREBBPMAP3K12CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265075-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-11691963-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | AJAX THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-20220411403-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. | 2022-12-29 | — | — | US | disclosed |
| WO-2022140527-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2021226261-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. (US) | 2021-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411403-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | JAK2, JAK3, STAT5B | BRD4 53/4885CREBBP 421/4885MAP3K12 516/4885 |
| US-20230265075-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | JAK2, JAK3, STAT5B | BRD4 53/4885CREBBP 421/4885MAP3K12 516/4885 |
| US-11691963-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | JAK2, JAK3, STAT5B | BRD4 53/4885CREBBP 421/4885MAP3K12 516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.